Camelina sativa is an oilseed crop rich in α-linolenic acid (ALA), an n-3 fatty acid (FA), and is resistant to harsh climates and pests. Previously, supplementation with camelina oil (CAM) in horses had no adverse effects on basic health parameters and had comparable skin and coat parameters as both flaxseed oil (FLX) and canola oil (OLA). Further, the plasma FA profile of horses was reflective of their respective treatment oil. The objective of this study was to assess the effects of dietary CAM supplementation on skin FA profile, immune, and inflammatory responses as compared to 2 commonly used oils in the equine industry, OLA and FLX, in healthy adult horses. Twenty-four adult horses, from 2 separate herds, were enrolled in this experiment. The horses underwent a gradual 4-wk fat acclimation period to sunflower oil (approximately 0.28% ALA), then were supplemented with either CAM (approximately 34.9% ALA), OLA (approximately 12.0% ALA), or FLX (56.0% ALA) at an inclusion rate of 0.37 g/kg body weight (BW) per day for an additional 16 wk. Immune and inflammatory responses were assessed by measuring antibody concentrations across time after sensitization to keyhole limpet hemocyanin (KLH) at weeks 10 and 12, and a subsequent delayed-type hypersensitivity (DTH) challenge. Skin biopsy samples were collected at weeks 0, 8, and 16, and FA composition was determined using gas-chromatography. All data were analyzed as a repeated measures ANOVA using PROC GLIMMIX in SAS. Antibody and DTH responses to KLH did not differ among groups (P = 0.262 and 0.813, respectively), and no treatment by time effects were observed (P = 0.764 and P = 0.817, respectively). Most FA in the skin changed in composition across time, with the sum of n-3 FA increasing (P < 0.001) and the sum of n-6 FA and skin n-6:n-3 ratio decreasing over time (P < 0.001 and P < 0.001, respectively). Only dihomo-γ-linolenic acid (P = 0.025) and the sum of n-3 FA (P = 0.031) had treatment-by-week effects. At week 16, the composition of eicosapentaenoic acid in the skin was greater in FLX than OLA, but neither differed from CAM (P = 0.049). These results suggest that ALA supplementation may beneficially impact skin FA profile. However, due to the small differences in n-3 FA and n-6:n-3 ratio among CAM, FLX, and OLA, a comparable skin FA profile, immune, and inflammatory response was observed among treatments at a dose of 0.37 g oil/kg BW. Therefore, CAM may be a suitable alternative to FLX in equine diets for the delivery of ALA.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/jas/skaf025 | DOI Listing |
ACS Nano
March 2025
School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, P. R. China.
Mesenchymal stromal cell (MSC) therapy holds great promise for treating myocardial infarction (MI). However, the inflammatory and reactive oxygen species (ROS)-rich environment in infarcted myocardium challenges MSC survival, limiting its therapeutic impact. In this study, we demonstrate that chemical modification of MSCs with anti-VCAM1 and polydopamine (PD) significantly enhances MSC survival and promotes cardiac repair.
View Article and Find Full Text PDFSkin Therapy Lett
March 2025
Center for Clinical Studies, Webster, TX, USA.
Psoriatic arthritis (PsA) is a chronic, inflammatory disease with heterogeneous clinical features. The pathogenesis of PsA involves a complex interplay of genetic, immunologic, and environmental factors, leading to the activation of the immune system and subsequent inflammation. Over the past decade, the understanding of the immune mechanisms underlying PsA has advanced significantly, particularly regarding the role of the interleukin-23/T helper 17 pathway in the disease process.
View Article and Find Full Text PDFSkin Therapy Lett
March 2025
University of Central Florida/HCA Healthcare Consortium, Tallahassee, FL, USA.
Seborrheic dermatitis (SD) is a chronic inflammatory skin disorder most commonly affecting areas rich in sebaceous glands, such as the scalp, face, axilla, and groin. Several factors can precipitate SD development, such as colonization of Malassezia, sebocyte activity, impaired immunity, and environmental influences. Topical antifungals, corticosteroids, and calcineurin inhibitors are the current mainstay treatment of SD.
View Article and Find Full Text PDFACS Biomater Sci Eng
March 2025
College of Stomatology, Chongqing Medical University, 426 Songshibei Road, Yubei District, Chongqing 401147, China.
Infected bone defects show a significant reduction in neovascularization during the healing process, primarily due to persistent bacterial infection and immune microenvironmental disorders. Existing treatments are difficult to simultaneously meet the requirements of antibacterial and anti-inflammatory treatments for infected bone defects, which is a key clinical therapeutic challenge that needs to be addressed. In this study, a conductive hydrogel based on copper nanoparticles was developed for controlling bacterial infection and remodeling the immune microenvironment.
View Article and Find Full Text PDFJ Immunol
January 2025
Center for Translational Immunology, Benaroya Research Institute, Seattle, WA, United States.
The CD2-depleting drug alefacept (LFA3-Ig) preserved beta cell function in new-onset type 1 diabetes (T1D) patients. The most promising biomarkers of response were late expansion of exhausted CD8 T cells and rare baseline inflammatory islet-reactive CD4 T cells, neither of which can be used to measure responses to drug in the weeks after treatment. Thus, we investigated whether early changes in T cell immunophenotypes could serve as biomarkers of drug activity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!